Capricor Announces Joint Publication, with US Army Institute, on Cardiosphere-Derived Exosomes As Potential Early Therapeutic for Shock; Publication Further Supports Capricor’s Exosome Platform Advancement

On August 4, 2021, Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) (Editor’s Note: EVs is an abbreviation for “extracellular vesicles” of which exosomes are a subset.) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular Vesicles Derived from Cardiosphere-Derived Cells As a Potential Antishock Therapeutic,” was published in the August 2021 issue of the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery, in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).

Login Or Register To Read Full Story